Refine
Year of publication
Document Type
- Article (11)
- Contribution to a Periodical (10)
Has Fulltext
- yes (21)
Is part of the Bibliography
- no (21)
Keywords
- ALL (1)
- AML (1)
- Chemiker (1)
- Dictyostelium discoideum (1)
- Frankfurt <Main> / Universität (1)
- MAP (1)
- MLL (1)
- Pharmazie (1)
- Phylogenetische Analyse (1)
- RNA-templated DNA repair (1)
Institute
Botanik zum Anfassen
(2013)
It is common knowledge that plants have been the world-wide most important source of medicines and that they still play this role in developing countries. However, up to now, complete lists of medicinal and aromatic plants (MAP) exist for comparatively few countries. A review of all lists know to the authors reveals the following results: A total of 20.7 % of the plant species analyzed by either publications or own research are or were used as MAP. However, regarding single countries, the differences are considerably high. Absolutely leading the list are China (36.2 %), Burkina Faso (35.2 %) and the Korean Republic (34.5 %). Also ahead of other countries or regions are the North of Benin (32.8 %) and the entire Pakistan (30.3 %). Still above average rank Great Britain (26.7 %) and Nepal (23.3 %), while the figures for Bul¬garia (21.0 %), Germany (20.2 %) and France (19.4 %) almost represent the average. Jordan (17.3 %), Vietnam (17.1 %), Sri Lanka (16.6 %), India (16.1 %) and Thailand (15.5 %) rank slightly beneath. Clearly below the average are the percentages of MAP for Hungary (12.2 %) and the USA (11.8 %). The average numbers of MAP in the Philippines (9.5 %) and Malaysia (7.7 %) fall far behind. Calculated on a worldwide scale, every fifth plant can be regarded as MAP. This number matches that from Bulgaria, France and Germany. In northern Benin, Burkina Faso, Korea, China and Pakistan, however, every third plant is or was used as MAP, whereas in Hungary and the USA only every eighth plant can be regarded as MAP. This number drops even further for the Philippines ore Malaysia where only every tenth or thirteenth plant can be attributed to medicinal or aromatic use. These differences might be due to various factors. A geographical component of the results is obvious: in most cases geographically close countries show similar percentages. A correlation between the total number of species and the fraction of those used as MAP cannot be confirmed. The countries with percentage of MAP > 30 % in common show that they belong either entirely (Burkina Faso, Benin) or at least in their rural areas to the poorest countries of the world so that it is (was) impossible for the majority of the people to buy "modern" MAP. In those countries the number of traditional healers outnumbers largely the number of modern doctors. Therefore, the tradition of folk medicine was maintained until today. Additionally, China, Korea and partially Pakistan have a very old and well documented tradition of folk medicine. Due to this documentation even in areas where today "modern MAP" are used, the knowledge was not lost. In neighboring countries or regions, which differ with respect to a more arid or a more humid climate, for the arid country (region) more MAPs are reported than for the humid one. The potential reasons for this phenomenon are discussed in the paper. For many countries the percentage given for MAP in literature is too low. But even these low values represent a striking argument for the importance of a world-wide conservation of biodiversity.
Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are associated with high-risk infant, pediatric, adult and therapy-induced acute leukemias. We used long-distance inverse-polymerase chain reaction to characterize the chromosomal rearrangement of individual acute leukemia patients. We present data of the molecular characterization of 1590 MLL-rearranged biopsy samples obtained from acute leukemia patients. The precise localization of genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) were determined and novel TPGs identified. All patients were classified according to their gender (852 females and 745 males), age at diagnosis (558 infant, 416 pediatric and 616 adult leukemia patients) and other clinical criteria. Combined data of our study and recently published data revealed a total of 121 different MLL rearrangements, of which 79 TPGs are now characterized at the molecular level. However, only seven rearrangements seem to be predominantly associated with illegitimate recombinations of the MLL gene (~ 90%): AFF1/AF4, MLLT3/AF9, MLLT1/ENL, MLLT10/AF10, ELL, partial tandem duplications (MLL PTDs) and MLLT4/AF6, respectively. The MLL breakpoint distributions for all clinical relevant subtypes (gender, disease type, age at diagnosis, reciprocal, complex and therapy-induced translocations) are presented. Finally, we present the extending network of reciprocal MLL fusions deriving from complex rearrangements.
Nach knapp vier Monaten Corona-Krise stellen sich auch der Wissenschaft viele Fragen: Sind bestimmte Teile der Gesellschaft stärker von den Folgen betroffen, klafft eine Gerechtigkeitslücke? Öffnen sich vielleicht aber auch Wege für neue medizinische, gesellschaftliche, wirtschaftliche und ökologische Ansätze? Forscherinnen und Forscher der Goethe-Universität aus verschiedenen Disziplinen wagen eine Zwischenbilanz und einen Ausblick.
CD4+CD25+ regulatory T cells (Tregs) represent a specialized subpopulation of T cells, which are essential for maintaining peripheral tolerance and preventing autoimmunity. The immunomodulatory effects of Tregs depend on their activation status. Here we show that, in contrast to conventional anti-CD4 monoclonal antibodies (mAbs), the humanized CD4-specific monoclonal antibody tregalizumab (BT-061) is able to selectively activate the suppressive properties of Tregs in vitro. BT-061 activates Tregs by binding to CD4 and activation of signaling downstream pathways. The specific functionality of BT-061 may be explained by the recognition of a unique, conformational epitope on domain 2 of the CD4 molecule that is not recognized by other anti-CD4 mAbs. We found that, due to this special epitope binding, BT-061 induces a unique phosphorylation of T-cell receptor complex-associated signaling molecules. This is sufficient to activate the function of Tregs without activating effector T cells. Furthermore, BT-061 does not induce the release of pro-inflammatory cytokines. These results demonstrate that BT-061 stimulation via the CD4 receptor is able to induce T-cell receptor-independent activation of Tregs. Selective activation of Tregs via CD4 is a promising approach for the treatment of autoimmune diseases where insufficient Treg activity has been described. Clinical investigation of this new approach is currently ongoing.